Bob Duggan knows how to spot a deal.
Buying — then holding — shares of cancer-fighting drug developer Pharmacyclics Inc. even as they sank under $1, Duggan took home $3.5 billion in cash and stock when the Sunnyvale company sold in 2015 to AbbVie Inc. (NYSE: ABBV) for $21 billion.
Now the former Pharmacyclics CEO, along with ex-Pharmacyclics COO Maky Zanganeh, have taken stakes in another promising-but-early-stage life sciences company, Pulse Biosciences Inc. (NASDAQ: PLSE). The Burlingame…
Bob Duggan knows how to spot a deal.
Buying — then holding — shares of cancer-fighting drug developer Pharmacyclics Inc. even as they sank under $1, Duggan took home $3.5 billion in cash and stock when the Sunnyvale company sold in 2015 to AbbVie Inc. (NYSE: ABBV) for $21 billion.
Now the former Pharmacyclics CEO, along with ex-Pharmacyclics COO Maky Zanganeh, have taken stakes in another promising-but-early-stage life sciences company, Pulse Biosciences Inc. (NASDAQ: PLSE). The Burlingame…